Pharvaris N. V. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially targeting angioedema and other bradykinin-mediated diseases.

The company generates revenue through the development and planned commercialization of its product candidates, primarily deucrictibant, which is being developed for the prevention and treatment of bradykinin-mediated angioedema attacks, including hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency, with revenue expected from future sales of these therapies upon regulatory approval.

The company operates through the following segments:

• deucrictibant immediate-release (IR) capsules for on-demand treatment of angioedema attacks.

• deucrictibant extended-release (XR) tablets for prophylactic treatment of angioedema attacks.

Pharvaris N. V. is positioned as a developer of novel oral therapies in the bradykinin B2 receptor antagonist space, differentiating itself from existing injectable treatments by offering convenience and comparable efficacy, with the potential to become a standard of care for both on-demand and prophylactic treatment of hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency.

The company serves patients suffering from bradykinin-mediated angioedema, including those with hereditary angioedema types 1 and 2, hereditary angioedema with normal C1-inhibitor, and acquired angioedema due to C1-inhibitor deficiency, with a focus on individuals aged 12 years and older in its clinical development programs.